Your session is about to expire
← Back to Search
Lenalidomide + Ipilimumab for Blood Cancers
Study Summary
This trial looks at the side effects of two cancer treatments: lenalidomide and ipilimumab. Lenalidomide stimulates or suppresses the immune system, and ipilimumab helps the body's immune system attack the cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't had any other cancers in the last 3 years, except for certain types.I have severe nerve pain or damage.You have had an auto-immune disease in the past.My kidney function is within the required range.My liver tests are within normal limits, except for conditions like Gilbert's disease.I have had a blood clot in my leg or lung recently.You are allergic to thalidomide, lenalidomide, or ipilimumab.I haven't had a serious infection needing treatment recently.I have HIV or hepatitis C, or I am managing hepatitis B with antiviral therapy.I do not have severe heart failure or recent heart attack.I have been treated with alemtuzumab within the required time frame.I have active GVHD or recent GVHD and am taking more than 10 mg of prednisone.I had a stem cell transplant within the last 6 months and my condition hasn't worsened.I do not have any current infections.My heart pumps well, with an ejection fraction of 45% or higher.My direct bilirubin level is below 1.6, not due to Gilbert's disease or medications.Your platelet count is higher than 75 billion per liter.I have not had immunotherapy or chemotherapy recently.You have a serious autoimmune disease that is currently causing a threat to your life.Your absolute neutrophil count is equal to or greater than 1.5 x 10^9 per liter.I can take care of myself but might not be able to do active work.I have a blood or lymph cancer.If you are able to become pregnant, you must have a negative pregnancy test within a specific time frame.Your lung function tests show that you can breathe out, take deep breaths, and exchange oxygen properly.Patients who have received a certain type of cell or tissue transplant from a donor and meet specific conditions.
- Group 1: Treatment (lenalidomide and ipilimumab)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Which individuals would qualify to partake in this clinical experiment?
"Qualified candidates must have been diagnosed with leukemia, and should be between 18-80 years of age. This investigation is taking on around 41 participants."
What are the applications of Lenalidomide in medical treatment?
"Lenalidomide is usually prescribed after two other systemic cancer treatments have been attempted. Its scope extends beyond this to encompass conditions like cutaneous melanoma, metastatic melanoma, and intermediate risk cases."
Is this experiment open to elderly participants aged 85 or above?
"According to the eligibility requirements, individuals aged between 18 and 80 may enroll in this clinical trial. In total, 664 trials are available for minors while 3782 studies target adults over 65."
What is the upper limit of participants engaged in this experiment?
"At this time, individuals are not being sought to participate in the study. It was initially posted on November 4th 2013 and last updated October 6th 2022. There exist 3,593 clinical trials actively recruiting patients with leukemia and 584 studies using Lenalidomide as an intervention currently seeking participants."
What safety protocols are in place for administering Lenalidomide to patients?
"Although lenalidomide has yet to be proven efficacious, there is data suggesting it can reduce harm. Consequently, this medication was assigned a score of 2 on our safety scale."
Is recruitment still ongoing for this trial?
"At present, no further individuals are being sought for this clinical trial which was originally posted on November 4th 2013 and last edited October 6th 2022. For persons looking to participate in a different medical study there are 3593 trials actively recruiting leukemia patients and 584 studies currently searching for Lenalidomide participants."
Has Lenalidomide been the subject of prior clinical investigations?
"Currently, 584 clinical trials are underway that involve Lenalidomide. Out of these studies, 94 have progressed to Phase 3. Trials for this medication primarily take place in Pittsburgh, Pennsylvania; however, a total of 33,571 locations across the world are currently running such tests."
Share this study with friends
Copy Link
Messenger